Intravenous immunoglobulin, known as IVIG, is one of the primary first-line treatments for autoimmune encephalitis, a condition in which the immune system mistakenly attacks the brain. The treatment works by flooding the body with pooled antibodies from thousands of donors, which dampens the misdirected immune attack through several overlapping pathways. How well it works, how it’s dosed, and when it makes sense compared to alternatives all depend on the specific type of autoimmune encephalitis involved and the severity of the case.
What IVIG Actually Does in Autoimmune Encephalitis
Autoimmune encephalitis happens when your immune system produces antibodies that target proteins on or in brain cells, causing inflammation, seizures, psychiatric symptoms, and cognitive decline. IVIG counteracts this through multiple mechanisms working simultaneously. It speeds up the breakdown of those harmful antibodies by saturating a receptor that normally recycles them, blocks immune-cell receptors that drive inflammation, dials down the activation of immune cells and inflammatory signaling molecules, and disrupts a cascade called complement activation that damages tissue.
IVIG also helps neutralize the circulating autoantibodies directly and modulates how the immune system’s signaling receptors behave, shifting the balance from attack mode toward tolerance.
One question researchers have explored is how IVIG gets its effects inside the brain, since the blood-brain barrier normally keeps large molecules out of neural tissue. Laboratory work has shown that a receptor called LRP1 can internalize IVIG inside living cells and then recycle it back to the cell surface, suggesting a possible transcytosis route that could shuttle the treatment across the barrier.
Dosing and Treatment Schedule
The standard initial dose for IVIG in autoimmune encephalitis is 2 grams per kilogram of body weight, typically divided over five consecutive days. For someone weighing around 70 kilograms, that means roughly 140 grams of immunoglobulin delivered across nearly a week of infusions. After the initial loading course, maintenance dosing usually follows at lower levels and longer intervals.
In a case series documenting treatment for anti-NMDA receptor encephalitis, one patient received the initial 2 g/kg course divided over five days and showed significant clinical improvement by day three. She then received four additional courses every five weeks as an inpatient, followed by ongoing maintenance at home at 1 g/kg divided over three days every 28 days. That pattern of a heavier induction dose tapering to a lighter maintenance schedule is common, though the exact intervals and durations vary based on clinical response and the antibody subtype involved.
How Quickly It Works
Speed of response matters enormously in autoimmune encephalitis, where every day of uncontrolled brain inflammation can mean lasting cognitive damage. A prospective study of IVIG in autoimmune encephalitis found that half of patients showed measurable improvement by day eight, defined as at least a one-point drop on a standard disability scale. By day 29, that figure climbed to roughly 86-89% of patients showing improvement. Among those who responded well to IVIG alone without needing additional rescue therapy, all six patients in the per-protocol group had favorable outcomes by day eight.
Those numbers sound encouraging, but they deserve context. Patients who did not respond well to IVIG by day eight were moved to rescue immunotherapy, meaning the treatment plan already anticipated that a meaningful fraction of people would need something beyond IVIG alone. About a third of the rescue group had favorable scores by day eight, and they went on to receive additional treatments.
Different Antibody Subtypes, Different Results
Autoimmune encephalitis is not one disease. The antibody target matters for how well IVIG works.
Anti-NMDA Receptor Encephalitis
This is the most widely recognized subtype, often affecting younger women and sometimes associated with ovarian tumors. A large retrospective study comparing IVIG alone, intravenous methylprednisolone (high-dose steroids) alone, and the combination of both found that the combination substantially outperformed either treatment on its own. The combined approach achieved a response rate of about 87%, compared to roughly 56% for IVIG alone and 69% for steroids alone. Patients receiving the combination also had better disability scores at three, six, and twelve months, and a much lower recurrence rate of about 5% compared to 24-27% with either treatment used solo.
Those findings have shifted clinical practice toward using IVIG and steroids together rather than choosing one or the other as the initial approach for anti-NMDA receptor encephalitis.
Anti-LGI1 and Anti-CASPR2 Encephalitis
These subtypes tend to appear in older adults and often present with seizures, including a distinctive type called faciobrachial dystonic seizures. IVIG has been tested in a rare randomized, placebo-controlled trial for this population. Three-quarters of patients receiving IVIG experienced at least a 50% reduction in seizure frequency, compared to about 22% in the placebo group. Among those who were specifically seropositive for LGI1 antibodies, the difference was even starker: 75% of the IVIG group responded versus none in the placebo group. Two LGI1-positive patients on IVIG became completely seizure-free during the blinded phase, while no one on placebo did.
Cognitive testing told a similar story. All eight LGI1-positive patients in the IVIG group showed stable or improved cognitive scores, compared to only two of five in the placebo group. For a disease that can cause severe memory problems, that cognitive benefit is as meaningful as seizure control.
Anti-LGI1 Encephalitis and Combination Therapy
Just as with anti-NMDA receptor encephalitis, combination therapy appears to outperform monotherapy for anti-LGI1 encephalitis. A real-world analysis comparing IVIG alone, steroids alone, and the two combined found that the combination achieved higher response rates, shorter time to improvement, and greater gains on clinical severity and disability scores.
IVIG Versus Plasma Exchange
Plasma exchange, sometimes called plasmapheresis, is the other major first-line treatment for autoimmune encephalitis. It works by physically removing the harmful antibodies from the blood. The natural question is which one works better.
A systematic review comparing the two across neurological disorders found they were mostly similarly effective when measured by clinical outcomes and severity scores. IVIG is generally easier to administer since it does not require central venous access or specialized equipment, while plasma exchange procedures have improved in simplicity and safety over time.
The picture gets more complicated in severe cases requiring intensive care. A study of anti-NMDA receptor encephalitis patients in the ICU found that plasma exchange was significantly more effective than IVIG. Of 29 patients initially treated with IVIG, only 13 improved, and the other 16 had to be switched to plasma exchange due to lack of improvement. All eight patients who received plasma exchange as their initial treatment improved. The median time to treatment response was about 30-36 days regardless of which treatment was used, but the key difference was that more patients responded to plasma exchange in this critically ill population.
This suggests that for milder or moderate cases, IVIG and plasma exchange are roughly interchangeable, but in severe ICU-level disease, plasma exchange may have an edge. The practical tradeoffs also matter: IVIG can be given through a regular IV line and even continued at home, while plasma exchange requires specialized equipment and venous access. For many hospitals, especially smaller or regional ones, IVIG is simply more accessible.
The Cost Question
IVIG is expensive. It is a blood product derived from thousands of donors, and global supply is constrained. A cost-minimization analysis comparing plasma exchange and IVIG for autoimmune neurological conditions found that plasma exchange was more cost-effective, which the researchers argued supports building plasma exchange capacity at regional neurology units, particularly given ongoing supply pressures on IVIG.
This is not just an academic point. IVIG shortages have affected hospitals in multiple countries, and when supply is tight, patients with autoimmune encephalitis compete for the same product needed by people with primary immunodeficiencies and other conditions. Clinicians sometimes have to weigh whether plasma exchange, rituximab, or other alternatives should be prioritized to conserve IVIG supply for patients who have no other options.
Treating Children with Autoimmune Encephalitis
Autoimmune encephalitis occurs in children as well as adults, and IVIG is a mainstay of pediatric treatment. A study of children treated with the combination of dexamethasone and IVIG found striking results: 90% of the patients were severely ill before treatment, but at final follow-up, about 90% had favorable outcomes. Complete recovery with no residual symptoms occurred in roughly 44% of cases, and the relapse rate was only about 2.4%. Children who did relapse responded well to retreatment with the same combination.
No severe adverse events were observed during treatment in that study, which is reassuring given that children can be more sensitive to fluid overload and infusion reactions. The combination worked for children in both the acute phase and those whose disease had progressed beyond the initial window, suggesting a relatively wide treatment window for this approach in pediatric patients.
Side Effects and Safety Considerations
IVIG is generally well tolerated, but it is not without risks. Side effects divide roughly into immediate infusion reactions and rarer delayed complications.
Common infusion reactions include headache, fever, chills, nausea, and muscle aches. These are typically mild and managed by slowing the infusion rate. More concerning but less common delayed adverse events include acute kidney injury, blood clots, aseptic meningitis (a sterile inflammation of the membranes around the brain), low white blood cell counts, and a type of anemia caused by the immune system attacking the patient’s own red blood cells.
Kidney problems deserve particular attention. They occur most often with IVIG products stabilized with sucrose, which can cause osmotic damage to the kidneys. People at higher risk include those with pre-existing kidney disease, diabetes, dehydration, high blood pressure, or advanced age, and those taking other medications that stress the kidneys. The practical guidance is straightforward: use non-sucrose IVIG products when possible, ensure good hydration before and during the infusion, keep the infusion rate slow and the concentration low, and monitor kidney function and urine output throughout.
Those same precautions, particularly slow infusion rates, adequate hydration, and dilute concentration, also help prevent blood clots and aseptic meningitis. One large study of 200 patients identified slow infusion and good hydration as the key preventive measures, recommending infusion rates no faster than 6 grams per hour at a dilution of 3%.
How IVIG Interferes with Diagnostic Testing
This is a practical wrinkle that clinicians and patients should be aware of. Because IVIG floods the body with pooled antibodies from many donors, it can confuse laboratory tests for autoantibodies. A study examining this effect found that after IVIG treatment, 90% of all tested blood samples became newly positive for antinuclear antibodies, particularly for a protein called Ro-52. These were false positives caused by the donor antibodies in the IVIG product, not by the patient’s own immune system.
On the flip side, the same study found that IVIG could also cause false negatives for the very antibodies clinicians are trying to track. About 13% of patients with known antibody positivity tested falsely negative after IVIG, and titers were misleadingly low in 37% of the remaining samples. For neural antibodies specifically, the news was better: 94% of samples did not develop false positive results for brain-targeted antibodies.
The takeaway is that antibody testing done shortly after an IVIG infusion should be interpreted cautiously. If you are being monitored for treatment response by tracking antibody levels, the timing of blood draws relative to your last IVIG dose matters. Clinicians typically try to draw blood just before the next scheduled infusion, when the IVIG level has had time to decline, to get more reliable results.
When IVIG Is Not Enough
First-line therapy in autoimmune encephalitis, whether IVIG, steroids, plasma exchange, or a combination, does not work for everyone. A significant minority of patients are labeled “refractory” because they fail to improve adequately. At that point, second-line treatments come into play, most commonly rituximab, which depletes the B cells that produce harmful antibodies, or cyclophosphamide, a broader immunosuppressant.
Even among patients who respond to IVIG initially, the disease can relapse. Maintenance IVIG infusions every few weeks can help sustain remission, but some patients need long-term immunosuppression with medications like mycophenolate or azathioprine. The decision about when to escalate from IVIG to second-line agents is one of the trickier calls in treating autoimmune encephalitis, balancing the desire to give first-line therapy adequate time to work against the urgency of stopping ongoing brain inflammation.
IVIG During Pregnancy
Autoimmune encephalitis can occur during pregnancy or the postpartum period, creating a difficult treatment situation. Many immunosuppressive drugs pose risks to the developing fetus, which limits the available options. IVIG is generally considered one of the safer immunotherapies during pregnancy because it consists of natural human antibodies rather than synthetic immunosuppressants. A systematic review of autoimmune encephalitis during pregnancy found that first-line immunotherapy, including IVIG and steroids either alone or combined, was the standard approach, while second-line agents were used in only a minority of cases.
The safety profile of IVIG in pregnancy is reassuring based on its long track record in other conditions like immune thrombocytopenia, where it has been used for decades without clear evidence of fetal harm. Still, treatment decisions during pregnancy involve weighing the risk of untreated brain inflammation, which can be severe and dangerous for both mother and baby, against the theoretical risks of any intervention.
Why the Blood-Brain Barrier Complicates Things
One of the ongoing puzzles in IVIG therapy for brain diseases is how a large protein molecule gets from the bloodstream into the central nervous system. IVIG antibodies are immunoglobulin G molecules, which are big by molecular standards and normally do not cross the blood-brain barrier freely. Yet IVIG clearly has effects on brain inflammation.
Part of the explanation is that in autoimmune encephalitis, the blood-brain barrier is often compromised by the inflammation itself, allowing more molecules to pass through. But research has also identified a possible active transport mechanism. The receptor LRP1, which is found on the cells lining brain blood vessels, can internalize IVIG and shuttle it across the cell to the other side, a process called transcytosis. Laboratory experiments showed that after LRP1 internalized IVIG, it recycled the antibodies back to the cell surface rather than destroying them, consistent with a transport function rather than a disposal one.
This mechanism is still being studied and is not definitively proven in humans, but it offers a plausible explanation for why IVIG has effects inside the brain even when the barrier is intact. Understanding this pathway could eventually lead to modifications that improve how much IVIG reaches the brain, potentially lowering the large doses currently required.
Practical Realities of Living on IVIG
For patients with autoimmune encephalitis who respond to IVIG, the treatment often becomes a long-term part of life. Maintenance infusions every three to five weeks, each lasting several hours, can continue for months or years. Some patients receive infusions at home through a visiting nurse service, while others go to infusion centers.
The infusions themselves are time-consuming. A single dose can take four to six hours to deliver safely, and patients often feel fatigued or unwell for a day or two afterward. Over time, venous access can become challenging, leading some patients to have a port placed for easier repeated infusions. The financial burden is also real: IVIG is among the most expensive treatments in medicine on a per-dose basis, and insurance coverage varies widely, sometimes requiring prior authorization for each course.
Despite these inconveniences, many patients on maintenance IVIG describe it as transformative. Autoimmune encephalitis before treatment can involve seizures, psychosis, profound memory loss, and an inability to function independently. When IVIG works, the improvement can be dramatic, sometimes visible within days of the first course. The gap between the severity of untreated disease and the burden of ongoing infusions is wide enough that most patients and their families consider the tradeoff worthwhile.